US · Healthcare · Biotechnology
EPS came in at -0.12 against a street estimate of -0.11 — a miss of 9.1%.
Analysts rate Nuvation Bio Inc a strong buy (12 buy, 1 hold, 0 sell out of 13) with an average price target of $13.00.
CONFIDENT IBTROZI revenue grew 25% to $23.2M, now 85% first-line patients. ROS1 market expanded 20% since launch. GSK's competing drug shows concerning CNS warnings and tolerability issues. Safusidenib program expanded to four studies across glioma segments. Q2 2026 IBTROZI EMA approval expected H1 2027, standard review. China/Japan royalties ongoing via Innovent and undisclosed partner. Analysts probed competitive positioning vs GSK's late approval, regulatory path for post-vorasidenib filing, and testing penetration in community oncology. Management emphasized early market capture of pretreated patients, FDA precedent for accelerated approval on smaller efficacy datasets, and ongoing initiatives to shift IO/chemo users toward ROS1 TKIs. 2026-08-06…
Full summary in the app.
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $44.951 million, up from $13.120 million in the third quarter of 2025. • Nine-month 2026 revenue w | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $44.951 million, compared with $13.120 million in Q3 2025. • Net product revenue was $27.457 million, c | 2026-11-04 |
| Quarterly report · Q2 2026 NUVATION BIO INC. - Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $258.6 million in cash and cash equivalents as of June 30, 2026 (up | 2026-08-06 |
| Results announced · Q3 2026 NUVATION BIO Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $31.7 million (product revenue $23.2 million + collaboratio | 2026-08-06 |
| Company announcement · Q2 2026 NUVATION BIO INC. - 8-K SUMMARY HEADLINE NUMBERS • Company completed a registered public offering of $287.5 million aggregate principal amount of co | 2026-07-06 |
| Material agreement · Q2 2026 NUVATION BIO INC. - 8-K SUMMARY HEADLINE NUMBERS • Completed public offering of $250.0 million aggregate principal amount of 0.75% Convertible Senio | 2026-06-30 |
| Shareholder vote results · Q2 2026 NUVATION BIO INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 21, 2026 with 389,931,796 shares present (289,931,796 Class A shares + 1, | 2026-05-27 |
| Quarterly report · Q1 2026 NUVATION BIO INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $533.7 million as of March 31, 2026 ($125.4 million cash + | 2026-05-04 |
Readable in the app.
| Announcement | Date |
|---|---|
| Strategic partnership announced with Eisai Co., Ltd. Nuvation Bio Inc. filed an 8-K on January 12, 2026, disclosing material information through press releases and a corporate presentation. The filing indicates announcements involving Nuvation | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Nuvation Bio Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.